
Responding to a Critique of the Industry
Critical comments of the drug evaluation process bring about strong reaction from industry.
In a recent analytical article and additional commentary published in BMJ, the drug evaluation process suffered heavy criticism. The controversial articles-which can be found below-elicited strong reactions from industry leaders including, Dr. Beat Widler, Professor Gerfried Nell, Dr. Uwe Gudat, and Thorsten Ruppert. Continue reading to hear clinical trials professionals defend and discuss the depictions made in the BMJ publications.
“
"
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.